Combo Anti-Spike Protein Antibody for Mild to Moderate COVID-19

Save

JAMA has published the BLAZE-1 study, showing significant SARS-CoV-2 viral load reduction at day 11 and less COVID-19 progression when combination anti-spike monoclonal antibody therapy (bamlanivimab and etesevimab) was given to mild to moderate, non-hospitalized COVID-19 patients.

Low Risk of TB with Secukinumab

Save

JAMA Dermatology has reported on a longitudinal cohort study of 12,319 secukinumab (SEC) treated patients (psoriasis, psoriatic arthritis, or ankylosing spondylitis); no new cases of active tuberculosis (TB) and very few cases of latent tuberculosis infection (LTBI) were f

Mortality Risk in Rheumatoid Lung Patients

Save

A Medicare claims analysis of rheumatoid arthritis (RA) patients showed that RA-associated interstitial lung disease (RA-ILD) was seen in nearly 5% of patients and was found to increase mortality risks, including respiratory and cancer mortality not explained by other factors.

Factors Predictive of SLE Flare After HCQ Taper/Discontinuation

Save

The benefits of hydroxychloroquine in lupus are many, but if you were to withdraw HCQ? A recent study of five Canadian cohorts, suggests that certain baseline variables, including age, race, and steroid use,  were predictive of flare in patients with SLE who tapered or discontinued treatment with hydroxychloroquine.

Inequities in Telemedicine During COVID-19

Save

Health equity in the telehealth age has assumed added importance since the COVID-19 pandemic began. The Federal Communications Commission estimates that about 21 million Americans don't have access to the Internet in their homes. Other sources estimate it is closer to 162 million.

Travel During COVID-19 Pandemic

Save

The CDC has addressed the effects and the issues of domestic and international travel on its website.  Below is a sampling of key advice.

Copay Assistance Programs Help Patients but Confuse Them Too

Save

"If you're having trouble paying for your medications, Drug Company X may be able to help."

RheumNow Podcast – Steroids, IVIG & the Vaccine (1.15.2021)

Save

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com. How to handle COVID19 Vaccine issues, IL-6 inhibition in COVID, Comorbidites in RA, IVIG in dermatomyositis, & more...

2020 Rheumatology Year in Review

Save

2020 was historic, memorable and game-changing. Under the cloud of COVID-19, there were many significant and memorable advances and setbacks for the rheumatology world. In our accounting of most read articles for 2020, (not surprisingly) 17/20 were COVID-related.

ProDERM Study: IVIG in Dermatomyositis

Save

The ProDERM study design and outcomes are previewed in Medicine; and as promised the results were revealed at ACR Convergence in November 2020 showing that IVIg is safe, effective and superior to placebo i(PBO) in patients with dermatomyositis (DM).

Long Term Safety and Efficacy of Tacrolimus in Lupus Nephritis

Save

Takeuchi et al has published their large experience with long-term tacrolimus use in lupus nephritis patients showing its real-world safety and efficacy.

Delays in Diagnosis of Axial Spondyloarthritis

Save

The diagnosis of axial spondyloarthritis (and anklylosing spondylitis) (axSpA) is often delayed and usually not diagnosed by rheumatologists; a recent metanalysis shows that longer delays were attributable to lower education levels, younger age at onset and absence of extra-articular manifes